Similar to CD19-targeted therapies, CD22 CAR-T treatments face resistance due to down-regulation or loss of CD22, allowing B-ALL to circumvent the treatment [25–28]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.